Chiasma, a biopharmaceutical company, is dedicated to developing and commercializing oral therapies to improve the lives of patients suffering from rare and severe chronic diseases. By utilizing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma aims to develop oral medications for conditions that currently require injections. In June 2020, the company received FDA approval for MYCAPSSA, the first and only oral somatostatin analog for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Chiasma is located in Needham, MA, with a subsidiary in Israel. The company's trademarks include MYCAPSSA, TPE, and CHIASMA.